Skip to main content

Table 2 Efficacy of microRNAs in the differential diagnosis of pancreatic cancer from healthy participants

From: Advances in biomarkers and techniques for pancreatic cancer diagnosis

Study MicroRNAs source Diagnostic power
AUC Sensitivity Specificity Accuracy
Training Validation Training Validation Training Validation Training Validation
Schultz et al Panel I Blood 0.86 0.83 0.85 0.85 0.64 0.48 0.74 0.72
Panel I + C* Blood 0.93 0.94 0.85 0.85 0.95 0.98 0.90 0.89
Panel II Blood 0.93 0.82 0.85 0.85 0.85 0.55 0.85 0.75
Panel II + C* Blood 0.97 0.93 0.85 0.85 0.98 0.90 0.92 0.86
Zou et al Six‐miRNA panel Serum 0.910 0.978 0.953 0.933 0.767 0.96   
Yu et al miR-25 Serum   0.939   0.825   0.9364   0.8895
miR-25 + C* Serum   0.985   0.975   0.9011   0.9895
Debernardi et al miR-143 Urine   0.862   0.833   0.885   
miR-143 + miR-30 Urine   0.923   0.833   0.962   
Yang et al miR-21 + miR-155 Stool   0.8111   0.9333   0.6667   
miR-21 + miR-155 + miR-216 Stool   0.8667   0.8333   0.8333   
Machida et al miR-1246 Salivary   0.814   0.667   1.0   
miR-4644 Salivary   0.763   0.750   0.769   
miR-1246 + 4644 Salivary   0.833   0.833   0.923   
  1. C* = CA19-9. Panel I is composed of miR-145, miR-150, miR-223, miR-636; Panel II is composed of miR-26b, miR-34a, miR-122, miR-126, miR-145, miR-150, miR-223, miR-505, miR-636, miR-885-5p; six‐miRNA panel contains let‐7b‐5p, miR‐192‐5p, miR‐19a‐3p, miR‐19b‐3p, miR‐223‐3p, and miR‐253p